| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Myomo Inc.$1.26
+0.08 (+6.58%)
Market Cap
-
EPS
-
P/E Ratio
-
Value Trade
907.36 K
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
76.02 K
52 Week Range
-
% held by Insiders
7.28 %
% held by Institutions
39.18 %
Enterprise Value
-
Total Shares
38.63 M
Short %
10.28 %
Float Shares
33.49 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MYO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
MYO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MYO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MYO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MYO Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
MYO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-MYO
May 13, 2026Myomo Appoints Joseph M. Manko to its Board of Directors BURLINGTON, MA. (
Myomo, Inc. has appointed Joseph M. Manko Jr. to its Board of Directors, effective May 9, 2026. Manko brings over 25 years of experience in investment banking, private equity, and corporate strategy, including his role as Senior Principal of Horton Capital Management LLC. His addition to the board aims to support Myomo's growth strategy and enhance shareholder value, while the company continues to develop its innovative technology for patients with neurological disorders and upper-limb paralysis.
Read more →-MYO
May 8, 2026Myomo Reports First Quarter 2026 Financial and Operating Results
Myomo, Inc. reported its financial results for Q1 2026, achieving revenue of $10.1 million, a 3% increase from the previous year. The company noted a significant shift towards recurring patient revenue sources, which now account for 49% of total revenue. Operating losses decreased, and gross margins improved, indicating positive operational trends. Myomo anticipates continued revenue growth in the upcoming quarter.
Read more →-MYO
Apr 16, 2026Myomo Appoints William J Febbo to its Board of Directors BURLINGTON, MA. (
Myomo, Inc. has appointed William J Febbo to its Board of Directors effective April 14, 2026. Febbo brings over 30 years of experience in healthcare and technology-driven businesses, which is expected to support Myomo's strategic initiatives for 2026 and beyond. He is recognized for his successful track record in guiding organizations through growth and transformation. This addition to Myomo's board is viewed as a crucial step towards strengthening the company's position in the wearable medical robotics market.
Read more →-MYO
Mar 9, 2026Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results Fourth quarter revenue of $11.4 million, full year revenue of $40.9 million 42% of fourth quarter revenue from recurring patient sources Rec
Myomo, Inc. announced its financial results for Q4 and full year 2025, reporting a revenue of $11.4 million for the quarter and $40.9 million for the year. The company emphasized growth from recurring patient sources, which constituted 42% of its fourth quarter revenue. Myomo recorded its highest number of authorizations and orders in the fourth quarter and introduced a revenue guidance for 2026 of $43 million to $46 million. However, the company faced challenges with a 6% decline in quarterly revenue compared to the same period last year and increased operating losses.
Read more →-MYO
Nov 10, 2025Myomo Reports Third Quarter 2025 Financial and Operating Results Revenue of $10.1 million 229 authorizations and orders, highest number this year Reiterates full year revenue guidance of $40 million to $42 million Confer
Myomo, Inc. reported its financial results for the third quarter of 2025, revealing revenue of $10.1 million, marking a 10% rise compared to the same period last year. The company noted its highest number of authorizations and orders, totaling 229, and reiterated its full-year revenue guidance of $40 to $42 million. However, Myomo faced challenges as it recorded an operating loss of $3.5 million, which is larger than the prior year's loss, alongside a decrease in gross margin due to increased costs. Despite these challenges, Myomo is optimistic about its new strategy to enhance patient referrals through its MyoConnect program.
Read more →-MYO
Aug 11, 2025Myomo Reports Second Quarter 2025 Financial and Operating Results Revenue of $9.7 million 816 patients added to the MyoPro pipeline Updates 2025 revenue guidance Conference call begins today at 4:30pm Eastern time BURLIN
Myomo, Inc. reported its second quarter 2025 financial results, showing a revenue of $9.7 million, which reflects a 28% increase from the same period in 2024. However, the company also faced challenges with lead quality, resulting in a significant operating loss of $4.6 million. Despite the addition of 816 new patients to the MyoPro pipeline, operating expenses surged by 65% year-over-year. Myomo is implementing changes to enhance lead generation through a shift in advertising strategy.
Read more →-MYO
Jun 18, 2025Myomo Provides Highlights of Today's Investor & Analyst Day Event Senior executives to provide an in-depth review of the Company's business model and discuss long-range aspirational financial metrics BURLINGTON, Mass. (
Myomo, Inc. hosted an Investor & Analyst Day event to review its business model and long-range financial goals. Management highlighted that lead generation has recovered from earlier challenges and expressed confidence in untapped market potential. Key discussions included plans for product enhancements, increasing manufacturing capacity, and achieving significant revenue growth aspirations. The event showcased the MyoPro's impact on improving the quality of life for patients with neurological disorders and disabilities.
Read more →-MYO
May 7, 2025Myomo Reports First Quarter 2025 Financial and Operating Results Revenue of $9.8 million Record 700 patients added to the pipeline More than 300 Certified Prosthetists Orthotists have completed initial MyoPro training Co
Myomo, Inc. reported strong financial results for Q1 2025, with revenue reaching $9.8 million, a significant increase of 162% from the previous year. The company successfully added a record 700 new patients to its pipeline and saw improvements in gross margin. However, operating expenses increased substantially, leading to an operating loss of $3.5 million. Despite these losses, management remains optimistic about revenue growth in the second half of 2025.
Read more →-MYO
Apr 10, 2025Myomo Announces Upcoming Changes to its Board of Directors BURLINGTON, Mass. (
Myomo, Inc. announced that directors Amy Knapp and Yitzchak Jacobovitz will not stand for re-election to the board. Their terms will conclude at the company's upcoming Annual Meeting in June 2025. The departing directors are optimistic about Myomo's future, particularly regarding its strategic direction and financial stability. The company intends to appoint new directors as part of its ongoing governance evolution.
Read more →-MYO
Mar 10, 2025Myomo's Fourth Quarter Financial Results Feature Record Revenue of $12.1 Million Generated first-ever positive quarterly cash flow from operations Received a record 233 MyoPro authorizations and orders with 657 additions
Myomo, Inc. reported significant financial results for the fourth quarter of 2024, featuring record revenue of $12.1 million, a 154% increase year-over-year. The company achieved its first positive cash flow from operations and received record authorizations for its MyoPro units. Management has set ambitious revenue guidance for 2025 between $50 million and $53 million. Despite these gains, the company also reported an increase in operating expenses and a slight net loss.
Read more →-MYO
Nov 6, 2024Myomo Reports Record Third Quarter Financial and Operating Results $9.2 million in revenue, raises full-year revenue guidance 225 MyoPro authorizations and orders with 316 patients in backlog at quarter end 645 additions
Myomo, Inc. reported significant financial growth for the third quarter of 2024, with revenues reaching a record $9.2 million, an 81% increase year-over-year. The company saw a substantial rise in its patient pipeline, totaling 1,263 candidates, and added a record 645 new patients during the quarter. Management anticipates fourth-quarter revenue between $9.5 million and $10.5 million, raising its full-year guidance to between $30 million and $31 million. Despite these positive metrics, the company continues to face an operational loss and increasing expenses.
Read more →-MYO
Aug 6, 2024Myomo Reports Second Quarter 2024 Financial Results Record revenue of $7.5 million Record 213 MyoPro authorizations and orders Record 550 additions to the pipeline, with 1,179 patients in the pipeline at quarter-end BOST
Myomo, Inc. reported its financial results for the second quarter of 2024, showcasing a record revenue of $7.5 million, a 26% increase from the previous year. The company achieved strong operational performance with a record of 213 MyoPro authorizations and orders, as well as adding 550 new patients to its pipeline, resulting in a total of 1,179 candidates. However, despite the revenue growth, Myomo experienced a net loss of $1.1 million, slightly worse than the same quarter last year, and operating expenses increased by 20%. Management expressed confidence in maintaining growth momentum and achieving cash flow breakeven in the following fourth quarter of 2024.
Read more →-MYO
Jul 8, 2024Myomo Reports Preliminary Second Quarter 2024 Revenues and Operating Metrics Expects record quarterly revenues of $7.2 million to $7.4 million, an increase of 92% to 97% sequentially Generates record pipeline additions,
Myomo, Inc. has reported preliminary revenues for Q2 2024, projecting record earnings between $7.2 million and $7.4 million. This marks an impressive sequential growth of 92% to 97% compared to Q1 2024. The company has also achieved record pipeline additions and authorizations, indicating robust operational performance. Furthermore, it has benefited from quicker payments from Medicare, allowing it to enhance its clinical and operational capacity.
Read more →-MYO
May 8, 2024Myomo Reports First Quarter 2024 Financial Results Record 275 patients in backlog, includes 180 authorizations and orders in Q1, up 48% over the prior year Record 493 MyoPro candidates added to the pipeline in Q1 Revenue
Myomo, Inc. reported its first quarter 2024 financial results, highlighting a record backlog of 275 patients and an increase in revenue by 9% to $3.8 million compared to the prior year. The company added a record 493 new candidates to its MyoPro pipeline, signifying growth in demand. However, the gross margin saw a decline, and the operating loss increased to $3.9 million, raising concerns about rising costs. Management remains optimistic about revenue growth in the upcoming quarters due to new reimbursement rates from Medicare.
Read more →-MYO
May 6, 2024Myomo Announces First Lump Sum Reimbursements for MyoPros Delivered to Medicare Part B Beneficiaries Under New CMS Fees Claims Remitted for Payment by All Four Billing Regions Orthotics and Prosthetics Providers Beginnin
Myomo, Inc. has announced that it is receiving lump sum reimbursements for its MyoPro device from Medicare under new CMS codes. This reimbursement process includes payments from all four billing regions, indicating equitable access for beneficiaries suffering from upper-limb paralysis. The company expects that this will facilitate clearer reimbursement pathways for healthcare providers. However, there are risks associated with securing sufficient reimbursement and maintaining operational stability in light of external market factors.
Read more →-MYO
Mar 28, 2024Myomo Appoints Heather Getz to its Board of Directors BOSTON (
Myomo, Inc. has appointed Heather Getz as a Class II director and chair of its audit committee, effective March 26, 2024. With over 25 years of experience in finance and healthcare leadership, Getz is expected to contribute to the company's growth. She currently serves as the executive vice president and chief financial officer of Butterfly Network Inc. The company develops medical robotics aimed at improving functionality for individuals with upper-limb paralysis and neurological disorders.
Read more →-MYO
Mar 7, 2024Myomo Reports Fourth Quarter and Full Year 2023 Financial Results Q4 total revenue of $4.8 million, up 18% over the prior year Addition of Medicare Part B patients to backlog results in record 183 MyoPro orders and insur
Myomo, Inc. reported its Q4 and full year 2023 financial results, showcasing an 18% increase in total revenue, which reached $4.8 million compared to the same quarter in the previous year. The company also achieved a record backlog of 230 units, driven by a significant rise in MyoPro orders and Medicare Part B patients. However, Myomo reported an operating loss of $2.4 million for Q4 2023. Looking ahead, the company anticipates revenue growth to accelerate in 2024, particularly from Medicare Part B patients.
Read more →-MYO
Mar 1, 2024CMS Posts Final Medicare DMEPOS Fee Schedule Rate for the MyoPro Fees for codes L8701 and L8702 are effective as of
On February 29, 2024, Myomo, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) released the final DMEPOS fee schedule rates for its MyoPro devices, effective April 1, 2024. The average reimbursement rates are set at $33,480.90 for the Motion W device and $65,871.74 for the Motion G device. This classification under the brace benefit category allows for lump-sum reimbursements, which is expected to greatly benefit eligible Medicare Part B beneficiaries. CEO Paul R. Gudonis expressed gratitude for CMS's acknowledgment of the MyoPro's benefits to patients.
Read more →-MYO
Jan 17, 2024Myomo Reports Preliminary Fourth Quarter Revenue and Backlog BOSTON (
Myomo, Inc. reported preliminary revenue for the fourth quarter of 2023, expecting figures between $4.6 million and $4.8 million, reflecting a notable increase compared to the previous year. Their backlog has also significantly grown, indicating strong demand for their MyoPro device, now classified by Medicare as a reimbursed brace. The company anticipates that deliveries to Medicare Part B beneficiaries will drive substantial revenue growth in the upcoming year, with long-term goals set for $100 million in annual revenues over the next five years.
Read more →-MYO
Nov 7, 2023Myomo Reports Third Quarter 2023 Financial Results Featuring Record Product Revenue and Authorizations Q3 total revenue of $5.1 million, up 28% over the prior year 156 MyoPro orders and insurance authorizations received,
Myomo, Inc. reported significant financial results for the third quarter of 2023, with total revenue reaching $5.1 million, a 28% increase from the previous year. The company saw growth in MyoPro orders and insurance authorizations, totaling 156 units. While the gross margin improved to 68.7%, the company also recorded an operating loss of $2.0 million, although this was an improvement over the prior year's loss. Myomo continues to focus on expanding its pipeline, particularly with Medicare Part B patients.
Read more →-MYO
Nov 6, 2023CMS Posts Proposed Medicare DMEPOS Fee Schedule Rate for the MyoPro for Review at the Upcoming HCPCS Public Meeting Public Meeting Scheduled for
Myomo, Inc. has announced that CMS has proposed a Medicare DMEPOS fee schedule for its MyoPro devices, which will be discussed at a public meeting on November 29, 2023. The proposed rates are $31,745.42 for the Motion W device and $62,457.28 for the Motion G device. The final rule, which classifies the MyoPro as a brace, will enable lump sum reimbursement starting January 1, 2024. However, the company acknowledges that these proposed rates may not be finalized or published as presented.
Read more →-MYO
Nov 2, 2023Myomo Announces that CMS has Classified the MyoPro Orthosis Under the Brace Benefit Category Standard Medicare Part B Patients now have access to the MyoPro, which will be reimbursed on a lump sum basis BOSTON (
Myomo, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has classified its MyoPro orthosis under the brace benefit category, allowing for lump sum reimbursement for Medicare Part B patients. This change aligns the payment methodology with other insurance plans and is aimed at enhancing access for individuals suffering from neurological disorders and upper-limb paralysis. The new classification is expected to be effective on January 1, 2024, following its publication in the Federal Register on November 13, 2023.
Read more →-MYO
Aug 24, 2023Myomo Receives Medicare Part B Reimbursement for First MyoPro Claims Appropriate payment amounts received on two MyoPro claims; Additional claims are under review while CMS rulemaking to re-classify the MyoPro to the bra
Myomo, Inc. announced it has received Medicare Part B reimbursement for two claims related to its MyoPro arm braces, designed for patients with upper-limb paralysis. This comes amid ongoing rulemaking by the Centers for Medicare & Medicaid Services (CMS), which could potentially reclassify MyoPro for lump sum payment under the brace benefit category. While this is a significant achievement for Myomo, the company still faces challenges, such as additional claims under review and past financial losses. They continue to engage with CMS to enhance patient access to their devices.
Read more →-MYO
Aug 9, 2023Myomo Reports Second Quarter 2023 Financial Results Featuring Year Over Year Growth in Revenue and Operating Metrics Q2 revenue of $6.0 million, including license revenue Nearly 1,000 prospective MyoPro candidates with k
Myomo, Inc. reported a strong financial performance in Q2 2023, achieving revenues of $6.0 million, reflecting significant year-over-year growth. Key operational metrics showed positive trends, including an increase in both revenue units and the patient pipeline for MyoPro candidates. However, the company continues to incur operating losses, and rising expenses alongside decreasing average selling prices could pose challenges. Myomo is preparing to expand its Medicare patient pipeline following new rules from the Centers for Medicare and Medicaid Services.
Read more →-MYO
May 10, 2023Myomo Reports First Quarter 2023 Financial Results Featuring 20% Year Over Year Increase in Product Revenue Implementation of virtual waiting room technology enabled a record 438 patients added to the pipeline, up 54% ov
Myomo, Inc. reported a 20% increase in product revenue for Q1 2023, achieving $3.4 million. The company's financial results were aided by a record addition of 438 patients to its pipeline, reflecting a 54% rise. While total revenue decreased by 11% compared to the previous year, management expressed optimism for future growth, citing improved advertising efficiencies and a decrease in cost per pipeline add. The company also noted a focus on working with established payers for better reimbursement opportunities.
Read more →-MYO
Apr 10, 2023Myomo Receives Technology License Fee Payment from China Joint Venture Company Payment of $1.7 million permits the start of activities to manufacture and sell the MyoPro in China BOSTON (
Myomo, Inc. has received a $1.7 million technology license fee from its joint venture company in China, allowing for the manufacturing and sale of its product, MyoPro, in the Chinese market. The payment coincides with the normalization of business conditions following the COVID-19 pandemic. Myomo aims to submit clinical evidence for regulatory approval to manufacture and sell the MyoPro in China, Hong Kong, Taiwan, and Macau. Despite the positive developments, the company faces several risks, including a history of operating losses and the need for regulatory approval to proceed with manufacturing and sales.
Read more →-MYO
Mar 13, 2023Myomo Reports Fourth Quarter and Full Year 2022 Financial Results Fourth quarter revenue was $4.0 million, up 2% sequentially 387 patients added to the pipeline in fourth quarter, up 75% compared with Q4 2021 Conference
Myomo, Inc. announced its financial results for Q4 and the full year of 2022, reporting a revenue of $4.0 million, which represents a 2% sequential increase. The company has made substantial improvements in its patient pipeline, adding 387 new candidates, reflecting a 75% increase from the same period last year. However, they noted a decrease in gross margin and continued operating losses, prompting a workforce reduction to manage costs. Myomo is focusing on reliable insurance payers for future growth and expects significant revenue growth in 2023.
Read more →-MYO
Jan 30, 2023Myomo Appoints Yitzchak Jacobovitz to its Board of Directors BOSTON (
Myomo, Inc. announced the appointment of Yitzchak Jacobovitz to its Board of Directors effective January 27, 2023. As the newest Class II director, Jacobovitz, who is a partner and lead healthcare analyst at AIGH Capital Management, will serve until the 2025 annual meeting. The addition of Jacobovitz brings Myomo's total board members to six, enhancing their expertise in healthcare investment as the company continues to build value for its stockholders. Myomo specializes in wearable medical robotics to aid individuals with upper-limb paralysis and neurological disorders.
Read more →-MYO
Jan 10, 2023Myomo Announces Initiative to Reduce Cash Burn Undertakes a reduction in force to enhance efficiency in its direct billing channel BOSTON
Myomo, Inc. has announced a reduction in force aimed at improving operational efficiency in its direct billing channel by eliminating approximately 12% of its workforce. This strategic move is expected to save more than $2 million annually, as the company seeks to extend its cash runway while obtaining coverage for its MyoPro device for Medicare patients. CEO Paul Gudonis stated that while unfortunate, the action was necessary to enhance operating leverage in light of ongoing financial challenges.
Read more →-MYO
Nov 10, 2022Myomo Reports Third Quarter 2022 Financial Results Featuring Strong Authorizations and Orders and Record Backlog Third quarter revenue of $4.0 million, up 8% sequentially 130 authorizations and orders results in a record
Myomo Reports Third Quarter 2022 Financial Results Featuring Strong Authorizations and Orders and Record Backlog Third quarter revenue of $4.0 million, up 8% sequentially 130 authorizations and orders results in a record-high backlog of 184 units Conference call begins at 4:30
Read more →-MYO
Aug 3, 2022Myomo Reports Second Quarter 2022 Financial Results and Record Number of Patient Pipeline Additions Second quarter revenue of $3.7 million up 18% over prior year Cost per pipeline addition cut in half over the last six m
Myomo Reports Second Quarter 2022 Financial Results and Record Number of Patient Pipeline Additions Second quarter revenue of $3.7 million up 18% over prior year Cost per pipeline addition cut in half over the last six months Conference call begins at 4:30 p.m. Eastern time to
Read more →-MYO
Jul 7, 2022Myomo Announces Second Quarter Preliminary Revenue and Record Pipeline Additions BOSTON (
Myomo Announces Second Quarter Preliminary Revenue and Record Pipeline Additions BOSTON (July 7, 2022) Myomo, Inc. (NYSE American: MYO) ( Myomo or the Company ), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorde
Read more →-MYO
May 11, 2022Myomo Reports First Quarter 2022 Financial Results Revenue of $3.9 million up 66% over prior year, product revenue of $2.9 million up 23% Pipeline of 924 MyoPro candidates up 14% over fourth quarter of 2021 Conference ca
Myomo Reports First Quarter 2022 Financial Results Revenue of $3.9 million up 66% over prior year, product revenue of $2.9 million up 23% Pipeline of 924 MyoPro candidates up 14% over fourth quarter of 2021 Conference call begins at 4:30 p.m. Eastern time today BOSTON (May 11
Read more →-MYO
Apr 4, 2022Myomo Reports Progress with China Joint Venture, Receives Partial Payment of Technology License Fee BOSTON (
Myomo Reports Progress with China Joint Venture, Receives Partial Payment of Technology License Fee BOSTON (April 4, 2022) Myomo, Inc. (NYSE American: MYO) ( Myomo or the Company ), a wearable medical robotics company that offers increased functionality for those suffering from
Read more →-MYO
Mar 9, 2022Myomo Reports Fourth Quarter and Full Year 2021 Financial Results Fourth quarter revenue of $4.0 million up 6% over prior year, full year revenue of $13.9 million up 83% over 2020 Fourth quarter gross margin of 77.4% up
Myomo Reports Fourth Quarter and Full Year 2021 Financial Results Fourth quarter revenue of $4.0 million up 6% over prior year, full year revenue of $13.9 million up 83% over 2020 Fourth quarter gross margin of 77.4% up 400 basis points over prior year Conference call begins a
Read more →-MYO
Jan 10, 2022Myomo Provides Update on MyoPro Insurance Reimbursement BOSTON, Mass (
Myomo Provides Update on MyoPro Insurance BOSTON, Mass (January 10, 2022) Myomo, Inc. (NYSE American: MYO) ( Myomo or the Company ), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis,
Read more →-MYO
Nov 10, 2021Myomo Third Quarter 2021 Financial Results Feature Record Revenue Revenue of $4.4 million up 128% over prior year, up 159% year-to-date Gross margin of 75% up 1,900 basis points over prior year Backlog increased to 177 u
Myomo Third Quarter 2021 Financial Results Feature Record Revenue Revenue of $4.4 million up 128% over prior year, up 159% year-to-date Gross margin of 75% up 1,900 basis points over prior year Backlog increased to 177 units Conference call begins at 4:30 p.m. Eastern time t
Read more →-MYO
Oct 15, 2021Myomo, Inc. Announces Agreements for Exercise of 2020 Investor Warrants BOSTON, Mass. (
Myomo, Inc. Announces Agreements for Exercise of 2020 Investor Warrants BOSTON, Mass. (October 15, 2021) Myomo, Inc. (NYSE American: MYO) ( Myomo or the Company ), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso
Read more →-MYO
Aug 9, 2021Myomo Second Quarter 2021 Financial Results Feature Significant Increases in Revenue and Gross Margin, Record Insurance Authorizations and Orders Revenue was $3.1 million, up 262% over prior year Gross margin was 71%, up
Myomo Second Quarter 2021 Financial Results Feature Significant Increases in Revenue and Gross Margin, Record Insurance Authorizations and Orders Revenue was $3.1 million, up 262% over prior year Gross margin was 71%, up 2,000 basis points over prior year Insurance authorizat
Read more →-MYO
Jun 8, 2021Myomo Provides Update on CMS Discussions BOSTON, Mass. (
Myomo Provides Update on CMS Discussions BOSTON, Mass. (June 8, 2021) Myomo, Inc. (NYSE American: MYO) ( Myomo or the Company ), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, tod
Read more →-MYO
May 5, 2021Myomo Reports First Quarter 2021 Financial Results Revenue of $2.3 million up 132% over prior year Gross margin of 73% up 500 basis points over prior year Q1 cash used in operations decreased 14% to $2.1 million Conferen
Myomo Reports First Quarter 2021 Financial Results Revenue of $2.3 million up 132% over prior year Gross margin of 73% up 500 basis points over prior year Q1 cash used in operations decreased 14% to $2.1 million Conference call begins at 4:30 p.m. Eastern time today BOSTON,
Read more →-MYO
Mar 10, 2021Myomo Reports Fourth Quarter and Full Year 2020 Financial Results Record Q4 2020 revenue of $3.8 million up 149% over prior year Full year 2020 revenue of $7.6 million up 98% vs. 2019 Q4 gross margin of 73% up 100 basis
Myomo Reports Fourth Quarter and Full Year 2020 Financial Results Record Q4 2020 revenue of $3.8 million up 149% over prior year Full year 2020 revenue of $7.6 million up 98% vs. 2019 Q4 gross margin of 73% up 100 basis points over prior year Q4 cash used in operations of $1.
Read more →-MYO
Jan 11, 2021Myomo Reports Preliminary Fourth Quarter and Full Year 2020 Results Fourth Quarter 2020 Revenue Expected to More than Double Compared With Fourth Quarter 2019 Quarterly cash utilization is the lowest since IPO in 2017 CA
Myomo Reports Preliminary Fourth Quarter and Full Year 2020 Results Fourth Quarter 2020 Revenue Expected to More than Double Compared With Fourth Quarter 2019 Quarterly cash utilization is the lowest since IPO in 2017 CAMBRIDGE, Mass. (January 11, 2021) Myomo, Inc. (NYSE Ameri
Read more →-MYO
Nov 10, 2020Myomo Third Quarter Financial Results Feature Record Revenue of $1.9 Million, up 218% Over the Prior Year Authorization backlog at a record 162 units, up 35% sequentially Cash utilization of $1.8 million, lowest since sc
Myomo Third Quarter Financial Results Feature Record Revenue of $1.9 Million, up 218% Over the Prior Year Authorization backlog at a record 162 units, up 35% sequentially Cash utilization of $1.8 million, lowest since scale-up activities began in 2018 Conference call begins a
Read more →-MYO
Aug 11, 2020Myomo Reports 2020 Second Quarter Financial Results Revenue Exceeds Projection as COVID-19 Restrictions Eased Authorization Backlog at Record Level of 120 Units, up 50% Sequentially Conference call begins at 4:30 p.m. Ea
Myomo Reports 2020 Second Quarter Financial Results Revenue Exceeds Projection as COVID-19 Restrictions Eased Authorization Backlog at Record Level of 120 Units, up 50% Sequentially Conference call begins at 4:30 p.m. Eastern time today CAMBRIDGE, Mass. (August 10 , 2020) Myo
Read more →-MYO
Jun 22, 2020Myomo Resumes Fitting MyoPro Patients and Deliveries as States Begin to Re-Open after COVID-19 Shutdowns Q2 Revenue Expected to be in the range of $0.6 million to $0.7 million CAMBRIDGE, Mass. (
Myomo Resumes Fitting MyoPro Patients and Deliveries as States Begin to Re-Open after COVID-19 Shutdowns Expected to be in the range of $0.6 million to $0.7 million CAMBRIDGE, Mass. (June 22, 2020) Myomo, Inc. (NYSE American: MYO) ( Myomo or the Company ), a wearable medical
Read more →-MYO
May 14, 2020Myomo Reports 2020 First Quarter Financial Results 21% Year-Over-Year Revenue Growth; 51% Sequential Increase in Authorization Backlog Conference call begins at 4:30 p.m. Eastern time today CAMBRIDGE, Mass. (
Myomo Reports 2020 First Quarter Financial Results 21% Year-Over-Year Revenue Growth; 51% Sequential Increase in Authorization Backlog Conference call begins at 4:30 p.m. Eastern time today CAMBRIDGE, Mass. (May 14, 2020) Myomo, Inc. (NYSE American: MYO) ( Myomo or the Company
Read more →-MYO
Apr 8, 2020Myomo Reports Accelerating Growth in MyoPro Pipeline and Record Backlog in the First Quarter of 2020, Provides Update on the Business Impact of COVID-19 CAMBRIDGE, Mass. (
Myomo Reports Accelerating Growth in MyoPro Pipeline and Record Backlog in the First Quarter of 2020, Provides Update on the Business Impact of COVID-19 CAMBRIDGE, Mass. (April 8, 2020) Myomo, Inc. (NYSE American: MYO) ( Myomo or the Company ), a wearable medical robotics comp
Read more →-MYO
Feb 6, 2020Myomo Reports Preliminary Fourth Quarter and Full Year 2019 Results CAMBRIDGE, MA.
Myomo Reports Preliminary Fourth Quarter and Full Year 2019 Results CAMBRIDGE, MA., February 6, 2020 Myomo, Inc. (NYSE American: MYO) ( Myomo or the Company ), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorder
Read more →-MYO
Nov 12, 2019Myomo Reports Third Quarter 2019 Results Growth Metrics Accelerating; Timing of Insurance Payments Affecting Short-term Revenue Growth
Myomo Reports Third Quarter 2019 Results Growth Metrics Accelerating; Timing of Insurance Payments Affecting Short-term Revenue Growth CAMBRIDGE, Mass., November 12, 2019 Myomo, Inc. (NYSE American: MYO) ( Myomo or the Company ), a wearable medical robotics company that offers
Read more →-MYO
Aug 8, 2019Myomo Reports Second Quarter 2019 Results Record Quarterly Revenues and 28% Sequential Expansion of Reimbursement Pipeline
Myomo Reports Second Quarter 2019 Results Record Quarterly Revenues and 28% Sequential Expansion of Reimbursement Pipeline CAMBRIDGE, Mass., August 8, 2019 Myomo, Inc. (NYSE American: MYO) ( Myomo or the Company ), a wearable medical robotics company that offers increased func
Read more →-MYO
May 13, 2019Myomo Reports First Quarter 2019 Results Reports 165% Year-over-Year Revenue Growth and Continued Expansion of Reimbursement Pipeline
Myomo Reports First Quarter 2019 Results Reports 165% Year-over-Year Revenue Growth and Continued Expansion of Reimbursement Pipeline CAMBRIDGE, Mass., May 13, 2019 Myomo, Inc. (NYSE American: MYO) ( Myomo or the Company ), a wearable medical robotics company that offers incre
Read more →-MYO
Mar 7, 2019Myomo Reports Fourth Quarter and Year End 2018 Financial Results Reports Record Revenues and Reimbursement Pipeline for the Fourth Quarter and Full Year
Myomo Reports Fourth Quarter and Year End 2018 Financial Results Reports Record Revenues and Reimbursement Pipeline for the Fourth Quarter and Full Year CAMBRIDGE, Mass., March 7, 2019 Myomo, Inc. (NYSE American: MYO) ( Myomo or the Company ), a wearable medical robotics compa
Read more →-MYO
Feb 7, 2019Myomo, Inc. Announces Proposed Public Offering of Common Stock
Myomo, Inc. Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass., February 7, 2019 Myomo, Inc. (NYSE American: MYO) ( Myomo or the Company ), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders a
Read more →-MYO
Feb 6, 2019Myomo Announces CFO Succession
Myomo Announces CFO Succession CAMBRIDGE, Mass., February 6, 2019 - Myomo Inc. (NYSE American MYO) ( Myomo, or the Company ), a wearable medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis, today announ
Read more →-MYO
Nov 5, 2018Myomo Announces Third Quarter 2018 Financial Results Achieved Revenue Growth of 25% and Reported 222 units in the Reimbursement Process
Myomo Announces Third Quarter 2018 Financial Results Achieved Revenue Growth of 25% and Reported 222 units in the Reimbursement Process CAMBRIDGE, Mass., November 5, 2018 Myomo, Inc. (NYSE American: MYO) ( Myomo or the Company ), a wearable medical robotics company that offer
Read more →-MYO
Aug 7, 2018Myomo Announces Second Quarter 2018 Financial Results Achieved Revenue Growth of 106%
Myomo Announces Second Quarter 2018 Financial Results Achieved Revenue Growth of 106% CAMBRIDGE, Mass., August 7, 2018 Myomo, Inc. (NYSE American: MYO) ( Myomo or the Company ), a wearable medical robotics company that offers increased functionality for those suffering from ne
Read more →-MYO
Jul 9, 2018Myomo Appoints Micah Mitchell as Chief Commercial Officer Company Establishes New Executive Position to Oversee Scaling Up of Commercial Operations
Myomo Appoints Micah Mitchell as Chief Commercial Officer Company Establishes New Executive Position to Oversee Scaling Up of Commercial Operations July 09, 2018 08:00 AM Eastern Daylight Time Mass. (BUSINESS WIRE) Myomo, Inc. (NYSE American: MYO) ( Myomo or the Company ), a w
Read more →-MYO
May 14, 2018Myomo Application for Medicare Codes Receives Favorable Preliminary Decision
Myomo Application for Medicare Codes Receives Favorable Preliminary Decision CAMBRIDGE, Mass., May 14, 2018 Myomo, Inc. (NYSE American: MYO) ( Myomo, or the Company ), a wearable medical robotics company, announces that the Centers for Medicare & Medicaid Services ( CMS ) has p
Read more →-MYO
May 9, 2018Myomo Reports First Quarter 2018 Results
Myomo Reports First Quarter 2018 Results CAMBRIDGE, Mass., May 9, 2018 Myomo, Inc. (NYSE American: MYO) ( Myomo or the Company ), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, to
Read more →-MYO
Mar 16, 2018REVISED NEWS RELEASE Myomo Reports Fourth Quarter and Year End 2017 Results
REVISED NEWS RELEASE Myomo Reports Fourth Quarter and Year End 2017 Results CAMBRIDGE, Mass., March 16, 2018 Myomo, Inc. (NYSE American: MYO) ( Myomo or the Company ), a commercial stage medical robotics company, today announced that it is updating its previous release that wa
Read more →-MYO
Mar 7, 2018Myomo Reports Fourth Quarter and Year End 2017 Results
Myomo Reports Fourth Quarter and Year End 2017 Results CAMBRIDGE, Mass., March 7, 2018 Myomo, Inc. (NYSE American: MYO) ( Myomo or the Company ), a commercial stage medical robotics company, today reports its financial results for the fourth quarter and year end December 31, 20
Read more →-MYO
Nov 30, 2017Myomo, Inc. Announces Pricing of Public Offering
Inc. Announces Pricing of Public Offering Mass., November 30, 2017 - Myomo, Inc. (NYSE American: MYO), a commercial stage medical robotics company, today announced that it has priced an underwritten public offering of 4,175,000 shares of its common stock and accompanying warran
Read more →-MYO
Nov 6, 2017Myomo, Inc. Reports Third Quarter 2017 Results
Inc. Reports Third Quarter 2017 Results Mass., November 6, 2017 - Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a commercial stage medical robotics company, today reports its financial results for the three and nine months ended September 30, 2017. and Achieveme
Read more →-MYO
Aug 14, 2017Inc.
Inc. Reports Second Quarter 2017 Results Mass., August 14, 2017 - Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a commercial stage medical robotics company, today reports its financial results for the three and six months ended June 30, 2017. and Achievements in
Read more →Competitive Position
How MYO ranks across every disease it competes inCompetitive Position is a premium feature
See how MYO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial